Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05297045 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
A Phase 2 study, sponsored by Regor Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT05297045: Clinical Trial Phase 2 study, sponsored by Regor Pharmaceuticals.
NCT05297045 is a Phase 2 study that was terminated before completion, run by Regor Pharmaceuticals. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05297045, a Phase 2 study, was terminated before completion, sponsored by Regor Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.
Interventions
- OTHER Placebo
- DRUG RGT001-075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05297045
The ClinicalTrials.gov registry entry for NCT05297045 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regor Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05297045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05297045 about?
NCT05297045 is a clinical study titled "A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes". This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequ...
What is the current status of trial NCT05297045?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2022-03-29. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT05297045?
The interventions under investigation include: Placebo (OTHER), RGT001-075 (DRUG).
Who is sponsoring clinical trial NCT05297045?
This trial is sponsored by Regor Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.